Clinical Trials
Study Title:
Randomized Phase III Trial of M-Folfirinox +/- Nivolumab vs. Folfox +/- Nivolumab for First Line Treatment of Metastatic HER-2 Negtive Gastroesophageal Addenocarcinoma
For more information about the trial above please contact the study team:
Medical University of South Carolina Principal Investigator, Albert Lockhart, at lockhara@musc.edu. Study Coordinator, Tianna Williams, at willitia@musc.edu.
Trial opened at the following institutions: Medical University of South Carolina |